Find Vimseltinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Dcc-3014, 1628606-05-2, Vimseltinib [inn], Vimseltinib [usan], Px9ftm69bf, Dcc3014
Molecular Formula
C23H25N7O2
Molecular Weight
431.5  g/mol
InChI Key
TVGAHWWPABTBCX-UHFFFAOYSA-N
FDA UNII
PX9FTM69BF

Vimseltinib
Vimseltinib is an orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, vimseltinib targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), vimseltinib inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and anti-tumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in the TME and allow for immune suppression; TAMs promote inflammation, tumor cell proliferation, angiogenesis, invasiveness and survival.
1 2D Structure

Vimseltinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
2.1.2 InChI
InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
2.1.3 InChI Key
TVGAHWWPABTBCX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C
2.2 Other Identifiers
2.2.1 UNII
PX9FTM69BF
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Dcc-3014

2. 1628606-05-2

3. Vimseltinib [inn]

4. Vimseltinib [usan]

5. Px9ftm69bf

6. Dcc3014

7. 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3h)-one

8. 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one

9. Dp-6865

10. 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3h)-pyrimidinone

11. 4(3h)-pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1h-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-

12. Unii-px9ftm69bf

13. Vimseltinib [who-dd]

14. Schembl16047448

15. Gtpl11190

16. Ex-a4700

17. Nsc828316

18. Who 11443

19. Nsc-828316

20. Example 10 [wo2014145025a2]

21. Hy-136256

22. Cs-0121044

23. 3-methyl-5-(6-methyl-5-{[2-(1-methyl-1h-pyrazol-4-yl)pyridin-4-yl]oxy}pyridin-2-yl)-2-[(propan-2-yl)amino]pyrimidin-4(3h)-one

24. Z6v

2.4 Create Date
2014-11-10
3 Chemical and Physical Properties
Molecular Weight 431.5 g/mol
Molecular Formula C23H25N7O2
XLogP31.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count6
Exact Mass431.20697307 g/mol
Monoisotopic Mass431.20697307 g/mol
Topological Polar Surface Area97.5 Ų
Heavy Atom Count32
Formal Charge0
Complexity740
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1628606-05-2 / Vimseltinib API manufacturers, exporters & distributors?

Vimseltinib manufacturers, exporters & distributors 1

46

PharmaCompass offers a list of Vimseltinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vimseltinib manufacturer or Vimseltinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vimseltinib manufacturer or Vimseltinib supplier.

PharmaCompass also assists you with knowing the Vimseltinib API Price utilized in the formulation of products. Vimseltinib API Price is not always fixed or binding as the Vimseltinib Price is obtained through a variety of data sources. The Vimseltinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Vimseltinib

Synonyms

Dcc-3014, 1628606-05-2, Vimseltinib [inn], Vimseltinib [usan], Px9ftm69bf, Dcc3014

Cas Number

1628606-05-2

Unique Ingredient Identifier (UNII)

PX9FTM69BF

About Vimseltinib

Vimseltinib is an orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), with potential antineoplastic, macrophage checkpoint-inhibitory and immunomodulating activities. Upon administration, vimseltinib targets and binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment (TME) and activity of CSF1R-dependent tumor-associated macrophages (TAMs), vimseltinib inhibits the immunomodulating activity by macrophages and enhances T-cell infiltration and anti-tumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in the TME and allow for immune suppression; TAMs promote inflammation, tumor cell proliferation, angiogenesis, invasiveness and survival.

Vimseltinib Manufacturers

A Vimseltinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vimseltinib, including repackagers and relabelers. The FDA regulates Vimseltinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vimseltinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Vimseltinib Suppliers

A Vimseltinib supplier is an individual or a company that provides Vimseltinib active pharmaceutical ingredient (API) or Vimseltinib finished formulations upon request. The Vimseltinib suppliers may include Vimseltinib API manufacturers, exporters, distributors and traders.

Vimseltinib GMP

Vimseltinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Vimseltinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vimseltinib GMP manufacturer or Vimseltinib GMP API supplier for your needs.

Vimseltinib CoA

A Vimseltinib CoA (Certificate of Analysis) is a formal document that attests to Vimseltinib's compliance with Vimseltinib specifications and serves as a tool for batch-level quality control.

Vimseltinib CoA mostly includes findings from lab analyses of a specific batch. For each Vimseltinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Vimseltinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vimseltinib EP), Vimseltinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vimseltinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty